Arrowhead Pharmaceuticals Inc (ARWR) Director William D. Waddill Sells 8,500 Shares of Stock

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Director William D. Waddill sold 8,500 shares of the firm’s stock in a transaction dated Friday, January 11th. The shares were sold at an average price of $14.77, for a total value of $125,545.00. Following the completion of the transaction, the director now owns 46,500 shares in the company, valued at approximately $686,805. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

ARWR traded down $0.13 during midday trading on Friday, reaching $14.87. 1,260,344 shares of the company were exchanged, compared to its average volume of 2,029,443. The company has a current ratio of 6.37, a quick ratio of 6.37 and a debt-to-equity ratio of 0.02. Arrowhead Pharmaceuticals Inc has a one year low of $4.77 and a one year high of $22.39. The stock has a market cap of $1.36 billion, a P/E ratio of -22.88 and a beta of 1.96.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, December 11th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.05. Arrowhead Pharmaceuticals had a negative return on equity of 57.18% and a negative net margin of 337.32%. The firm had revenue of $11.26 million for the quarter, compared to analysts’ expectations of $3.73 million. As a group, equities analysts forecast that Arrowhead Pharmaceuticals Inc will post 1.49 EPS for the current year.



Several equities analysts recently issued reports on the company. Cantor Fitzgerald set a $18.00 price target on Arrowhead Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 2nd. Jefferies Financial Group raised their price target on Arrowhead Pharmaceuticals to $24.00 and gave the company a “buy” rating in a report on Friday, September 14th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $25.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, October 4th. BidaskClub cut Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, October 6th. Finally, Chardan Capital reiterated a “buy” rating and issued a $24.50 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, December 17th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Arrowhead Pharmaceuticals currently has an average rating of “Buy” and an average target price of $21.36.

A number of institutional investors and hedge funds have recently modified their holdings of ARWR. Great West Life Assurance Co. Can bought a new position in Arrowhead Pharmaceuticals during the second quarter worth about $106,000. Stratos Wealth Partners LTD. bought a new position in Arrowhead Pharmaceuticals during the third quarter worth about $123,000. Meeder Asset Management Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth about $129,000. Macquarie Group Ltd. acquired a new stake in shares of Arrowhead Pharmaceuticals during the second quarter worth about $151,000. Finally, BlueMountain Capital Management LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the second quarter worth about $188,000. Hedge funds and other institutional investors own 60.45% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://dakotafinancialnews.com/2019/01/13/arrowhead-pharmaceuticals-inc-arwr-director-william-d-waddill-sells-8500-shares-of-stock.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Featured Article: What are CEFs?

Insider Buying and Selling by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply